# ClinicalTrials.gov record NCT02572323

> PeptideScanner retained ClinicalTrials.gov record NCT02572323 at 2026-07-30T16:22:22.328Z. Its registry update date was 2026-03-12, and PeptideScanner's reviewed identity mapping was tesamorelin.

- Evidence object: `story:clinicaltrials-gov-nct02572323-tesamorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02572323-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02572323-tesamorelin-v1.json
- Content SHA-256: `547c887735cd71cfc26c553f1a2e545a7b75d2e64b2f419e457baad59f75b187`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT02572323 ([`ctg-observation-nct02572323-2026-03-12-d7d7392d6688`](#source-ctg-observation-nct02572323-2026-03-12-d7d7392d6688))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02572323 at 2026-07-30T16:22:22.328Z. Its registry update date was 2026-03-12, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct02572323-2026-03-12-d7d7392d6688`](#source-ctg-observation-nct02572323-2026-03-12-d7d7392d6688))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02572323 at 2026-07-30T16:22:22.328Z. Its registry update date was 2026-03-12, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct02572323-2026-03-12-d7d7392d6688`](#source-ctg-observation-nct02572323-2026-03-12-d7d7392d6688))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02572323-2026-03-12-d7d7392d6688`](#source-ctg-observation-nct02572323-2026-03-12-d7d7392d6688))

## Sources

<a id="source-ctg-observation-nct02572323-2026-03-12-d7d7392d6688"></a>
- **ClinicalTrials.gov record NCT02572323 · retained source version 2026-03-12:d7d7392d6688e4b6ab8add8cdb202339b63a846e03517c7b10a4debf1f4650df** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02572323) (`ctg-observation-nct02572323-2026-03-12-d7d7392d6688`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02572323." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02572323-tesamorelin-v1.json SHA-256: 547c887735cd71cfc26c553f1a2e545a7b75d2e64b2f419e457baad59f75b187.